WuXi Biologics (2269) investor relations material

Technology and Platform Innovation

• Introduced PatroLab, an AI-enabled process monitoring system for fully automated, human-free manufacturing within 3-5 years, enabling real-time, cloud-based monitoring of 40 parameters and proactive control.

• Launched WuXia TrueSite, a fourth-generation cell line technology, accelerating development, achieving higher titers, improved product quality, and reducing cost of goods by up to 60%, with over 50 projects since launch and first IND approval expected in June 2026.

• AI and automation are integrated across R&D, development, and manufacturing, accelerating timelines and improving outcomes.

• Published scientific papers increased from 3 in 2017 to 54 in 2025, reflecting rapid innovation.

Business Momentum and Project Pipeline

• Added 69 new projects in the first four months, a 50% year-over-year increase, with two-thirds from US and Europe; over 50% YoY growth in bi- & multi-specific projects.

• Project capacity is expanding from 200 to 300 annually by 2027, with headcount increasing only 10% due to AI efficiencies.

• 78 late-stage and 25 CMO projects provide a strong foundation for manufacturing revenue growth.

• Signed a major MOU with a global MNC for 16 programs, with potential US$5b+ over 10 years.

• Top three manufacturing projects will each reach over $100 million in revenue in 2026, with manufacturing revenue growth expected at 30% CAGR.

Bi- & Multi-specifics and Royalty Framework

• Nearly 20 royalty-bearing bi- & multi-specific projects, with one of the industry's largest and most advanced portfolios.

• Higher technical barriers in development and manufacturing drive greater program retention.

• Multi-layer royalty framework enables asset-light participation in downstream product economics, including cell line royalties for external manufacturing.

• Margin profile for biosimilars expected to be similar to new products due to technology-driven cost advantages.

• Biosimilar projects are expected to double in three years, driven by technology advantages and regulatory changes.